Clinical cancer research : an official journal of the American Association for Cancer Research

Clin Cancer Res · ISSN (e) 1557-3265 · 44 papers in corpus
2015
doi:10.1158/1078-0432.ccr-14-2467 ·PMID:26240291

PurposeNoninvasive biomarkers for early detection of pancreatic ductal adenocarcinoma (PDAC) are currently not available. Here, we aimed to identify a set of urine proteins able to distinguish patients with early-stage PDAC from healthy ind…

article 2014
doi:10.1158/1078-0432.ccr-14-1338 ·PMID:25294912

PURPOSE: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions. Endometrioid and clear-cell ovarian tumors p…

2014
doi:10.1158/1078-0432.ccr-14-0463 ·PMID:25294909

PurposeNovel therapeutic regimens are needed to improve dismal outcomes associated with late-stage ovarian cancer. Oncolytic viruses are currently being tested in patients with ovarian cancer. Here, we tested the therapeutic efficacy of com…

article 2013
doi:10.1158/1078-0432.ovca13-b71

Abstract Introduction: Endometriosis is a largely benign, chronic inflammatory disease defined by the presence of endometrial-like glands surrounded by stroma. Epidemiologic studies suggest that endometriosis is an independent risk factor f…

2013
doi:10.1158/1078-0432.ccr-13-0209 ·PMID:23918603

PurposeTo identify metabolic pathways that are perturbed in pancreatic ductal adenocarcinoma (PDAC), we investigated gene-metabolite networks with integration of metabolomics and transcriptomics.Experimental designWe conducted global metabo…

article 2013
doi:10.1158/1078-0432.ccr-12-2726 ·PMID:23362326

PURPOSE: Endometriosis, a largely benign, chronic inflammatory disease, is an independent risk factor for endometrioid and clear cell epithelial ovarian tumors. We aimed to identify plasma miRNAs that can be used to differentiate patients w…

letter 2013
doi:10.1158/1078-0432.ccr-13-0561 ·PMID:23616637

In a recent article, Suryawanshi and colleagues reported that alterations of plasma microRNAs (miRNA or miR) may be novel biomarkers for endometriosis and endometriosis-associated ovarian cancer (1). However, we have some concerns about the…

letter 2013
doi:10.1158/1078-0432.ccr-13-1022 ·PMID:23616635

We are pleased that our research (1) has generated interest in the scientific community, and we are happy to provide our reply to the comments submitted by Dr. Haifeng Qiu.The major concern addressed by Dr. Qiu is that the upregulation of p…

other 2011
doi:10.1158/1078-0432.CCR-11-1388 ·PMID:21903772

PURPOSE: Genetically engineered mouse (GEM) models of ovarian cancer that closely recapitulate their human tumor counterparts may be invaluable tools for preclinical testing of novel therapeutics. We studied murine ovarian endometrioid aden…

2010
doi:10.1158/1078-0432.ccr-09-2105 ·PMID:20233889

PurposeAdvanced ovarian clear cell carcinoma (CCC) is one of the most aggressive ovarian malignancies, in part because it tends to be resistant to platinum-based chemotherapy. At present, little is known about the molecular genetic alterati…

2009
doi:10.1158/1078-0432.ccr-08-2525 ·PMID:19383821

PurposeThe effects of reproductive hormones on ovarian cancer growth are not well understood. Here, we examined the effects of estrous cycle variation and specific reproductive hormones on ovarian cancer growth.Experimental designWe investi…

2009
doi:10.1158/1078-0432.ccr-09-0365 ·PMID:19690197

PurposeMammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer. This study aimed to examine the role of mTOR as a therapeutic targ…

article 2008
doi:10.1158/1078-0432.ccr-07-1614 ·PMID:18172249

PURPOSE: Endometriotic cysts are known to transform into ovarian cancers, such as clear cell and endometrioid carcinomas. We hypothesized that an iron-rich environment produced by the repetition of hemorrhage in the endometriotic cysts duri…

2008
doi:10.1158/1078-0432.ccr-08-1387 ·PMID:18980979

PurposeA meta-analytic approach was used to estimate the frequency of: (a) microsatellite instability-high (MSI-H) phenotype in unselected ovarian cancers and (b) various histologic subtypes of mismatch repair (MMR)-deficient epithelial ova…

2008
doi:10.1158/1078-0432.ccr-08-1557 ·PMID:18794069

Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient…

2007
doi:10.1158/1078-0432.ccr-07-0164 ·PMID:17545545

PurposeThese studies were designed to determine whether the synthetic steroid mifepristone inhibits ovarian cancer growth in vitro and in vivo and the molecular mechanisms involved.Experimental designThe effect of mifepristone on ovarian ca…

article 2003
·PMID:14613992

PURPOSE: It has been hypothesized that circulating androgens may be involved in the development of ovarian cancer. The androgenic medication, danazol, and the antiandrogenic medications, leuprolide and nafarelin, are commonly used in the tr…

other 2002
·PMID:12060613

PURPOSE: The purpose of this study was to examine ovarian cancer cells for the expression of decorin, a proteoglycan component of the cell matrix that can inhibit cancer cell growth. EXPERIMENTAL DESIGN: Cultured ovarian cancer cells and s…

other 2000
·PMID:10690545

The DNA base excision repair pathway is responsible for the repair of alkylation and oxidative DNA damage. A crucial step in the base excision repair pathway involves the cleavage of an apurinic/apyrimidinic (AP) site in DNA by an AP endonu…